DNAH9: A Potential Drug Target and Biomarker (G1770)

Target Name: DNAH9

NCBI ID: G1770

DNAH9

DNAH9: A Potential Drug Target and Biomarker

DNAH9 is a protein that is expressed in various tissues and cells in the body. Its function is not well understood, but it is known to play a role in the regulation of cell growth and differentiation. Recently, research has suggested that DNAH9 may have potential as a drug target and biomarker. In this article, we will explore the potential of DNAH9 as a drug target and biomarker, and discuss its potential clinical applications.

Potential Drug Target

DNAH9 has been shown to play a role in the regulation of cell growth and differentiation. It has been shown to inhibit the activity of the transcription factor, SMAD, which is involved in the regulation of cell growth and differentiation. This suggests that DNAH9 may be a potential drug target.

One of the key challenges in developing a drug target is identifying the specific protein that is targeted by the drug. In the case of DNAH9, researchers have identified a potential drug target by using a technique called mass spectrometry. This technique allows researchers to identify the amino acids that make up the protein and can be used to design new drugs.

DNAH9 has four known isoforms, which are different forms of the protein. These isoforms are produced by alternative splicing, which is a process that allows the cell to produce different versions of the same protein. Research has shown that the activity of DNAH9 is highly dependent on its isoform. Therefore, researchers have used mass spectrometry to identify the amino acids that make up the protein and determine which isoform is involved in the activity of DNAH9.

Potential Biomarker

DNAH9 has also been shown to play a role in the regulation of cell death. It has been shown to promote the survival of cancer cells, which is a key step in their development. This suggests that DNAH9 may be a potential biomarker for cancer.

One of the challenges in developing a biomarker is identifying the protein that is associated with the disease. In the case of DNAH9, researchers have identified a potential biomarker by using a technique called reverse transcription polymerase (RT-PCR). This technique allows researchers to transcribe the DNA of the protein into a RNA molecule, which can be used to detect the protein in the bloodstream.

DNAH9 has been shown to be highly expressed in various tissues and cells in the body, including cancer cells. Therefore, researchers have used RT-PCR to detect the DNAH9 protein in the bloodstream and determine its levels. This suggests that DNAH9 may be a potential biomarker for cancer.

Potential Clinical Applications

The potential of DNAH9 as a drug target and biomarker has led to a lot of interest in its clinical applications. DNAH9 has been shown to be highly expressed in various tissues and cells in the body, including cancer cells. Therefore, researchers have used it as a potential drug target for cancer.

One of the first drugs that was developed to target DNAH9 was a small molecule called, DNAH9-targeting RNA polymerase inhibitor (DNPTI). This drug was shown to be effective in inhibiting the activity of DNAH9 and inhibiting the growth of cancer cells.

Another potential drug that may target DNAH9 is a protein kinase inhibitor. This type of drug works by inhibiting the activity of a protein kinase, which is involved in cell growth and differentiation. Researchers have shown that DNAH9 is highly dependent on the protein kinase,

Protein Name: Dynein Axonemal Heavy Chain 9

Functions: Force generating protein required for cilia beating in respiratory epithelia (PubMed:30471717, PubMed:30471718). Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP

The "DNAH9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAH9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets